Gideon Capital Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Gideon Capital Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-5,578	Closed	-$495K	–	282
2019 Q1	$495K	Sell	5,578 -3,585	-39%	-$332K	0.18%	170
2018 Q4	$780K	Buy	9,163 +4,124	+82%	+$392K	0.32%	92
2018 Q3	$489K	Buy	5,039 +677	+16%	+$67.6K	0.23%	148
2018 Q2	$411K	Buy	+4,362	New	+$382K	0.21%	187
2018 Q1	–	Sell	-2,862	Closed	-$255K	–	351
2017 Q4	$255K	Sell	2,862 -1,536	-35%	-$134K	0.22%	200
2017 Q3	$409K	Buy	4,398 +2,088	+90%	+$185K	0.4%	72
2017 Q2	$210K	Sell	2,310 -1,721	-43%	-$157K	0.23%	223
2017 Q1	$354K	Sell	4,031 -1,922	-32%	-$171K	0.21%	191
2016 Q4	$494K	Buy	+5,953	New	+$512K	0.32%	92
2014 Q3	–	Sell	-11,941	Closed	-$743K	–	273
2014 Q2	$743K	Buy	+11,941	New	+$721K	0.27%	120

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Gideon Capital Advisors's BMRN Position: Q2 2019 in Review

Gideon Capital Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2019, closing a stake of 5,578 shares — an estimated $495K sold.

Gideon Capital Advisors first reported a position in BMRN in Q2 2014 and held it in 10 quarters. The position peaked at $780K in Q4 2018. 482 funds tracked by Wall St. Rank hold BMRN as of Q2 2019.

Gideon Capital Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
Gideon Capital Advisors sold 5,578 BioMarin Pharmaceuticals shares in Q2 2019, an estimated $495K.
Gideon Capital Advisors first reported a position in BioMarin Pharmaceuticals in Q2 2014 and held it in 10 quarters.
Gideon Capital Advisors's BioMarin Pharmaceuticals position peaked at $780K in Q4 2018.
482 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2019.

Based on Gideon Capital Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.